KB-1848

Itepekimab

60896

Background of Itepekimab

IL-33 is a proinflammatory cytokine localised to the nuclei of a variety of cell types, including epithelial and endothelial cells. When airway epithelial cells are exposed to airborne allergens, viruses, cigarette smoke or air pollutants, IL-33 is released and acts as a short-lived alarmin molecule, which is proposed to initiate and amplify both type 1 and type 2 inflammation. Itepekimab, a novel fully human anti-IL-33 monoclonal antibody, blocks the effects of IL-33. The improvement in both exacerbation rate and lung function observed with itepekimab in former smokers with COPD supports the hypothesis that IL-33 might be important in both acute and chronic inflammatory airway responses.

Specifications

Catalog Number	KB-1848
Antibody Name	Itepekimab
Isotype	Human IgG4-S228P,kappa
FC Muations	S228P
Target	IL33
Species Reactivity	Human
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	50 mM sodium citrate,150mM NaCl,pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Validation	ELISA
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

Rabe KF, Martinez FJ, Bhatt SP, Kawayama T, Cosio BG, Mroz RM, Boomsma MM, Goulaouic H, Nivens MC, Djandji M, Soler X, Liu Y, Kosloski MP, Xu CR, Amin N, Staudinger H, Lederer DJ, Abdulai RM. AERIFY-1/2: two phase 3, randomised, controlled trials of itepekimab in former smokers with moderate-to-severe COPD. ERJ Open Res. 2024 Sep 23;10(5):00718-2023.